Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).
Epistemonikos ID: fa82433f3bbb3b0ed4f55943344199ab6b39afac
First added on: May 02, 2020